Clinical Trial Update: Aflac ST1001 Prolonged Isotretinoin [Phase 1]

View source ↗

Summary

A Phase 1 trial of Aflac ST1001 Prolonged Isotretinoin for neuroblastoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Aflac ST1001 Prolonged Isotretinoin (isotretinoin)

Snippet

Sponsor: Emory University | Conditions: Neuroblastoma | Phase 1 | Status: WITHDRAWN